Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication

According to WHO data, there are about 18.6 million deaths annually due to heart attacks and strokes. Preventive drugs, such as aspirin play an important role in cutting down the chance of heart attacks and strokes in patients with the disease.

That is why it is very important to know the value of drugs for CVD, which accounts for the highest levels of mortality at WHO. Recent research highlights the importance of medication, in managing CVD.

But while Aspirin and other drugs can help in CVD prevention, advanced screening tools such as ultrasound can help detect events of cardiovascular before they can become deadly. Carotid artery ultrasound for identifying atherosclerosis is a concrete example of the use of ultrasound in preventing cardiovascular disease.​

The ASPREE trial conducted in 2018 focused on studying the effects of dose aspirin on healthy elderly individuals. The research findings indicated that although aspirin did not notably increase disability survival it did show a decrease in cardiovascular events among high-risk groups (as shown below).

However, the study also pointed out the risk of bleeding, emphasizing the need for personalized evaluations of risks and benefits.

The ASCEND trial focused on people with diabetes, a group known to be at heightened risk for disease. Results from this study revealed that using aspirin resulted in a 12% drop in incidents. Nevertheless, it also led to a 29% rise in bleeding instances highlighting the complexities surrounding aspirin treatment.

Moreover, the ARRIVE trial examined how effective aspirin is for individuals with risk. Although the trial did not demonstrate a decrease in cardiovascular events statistically it shed light on important aspects of aspirin therapy in primary prevention.

These studies collectively showcase how aspirin serves as both a measure against cardiovascular issues and as a potential risk factor for bleeding. Therefore while preventive medication plays a role in managing diseases it is essential to carefully assess individual risks and seek advice from healthcare professionals.

This advice is intended for adults aged 40 and above without known disease (including heart attacks or strokes) who are not at higher risk, for bleeding (e.g., no history of stomach ulcers recent bleeding incidents certain medical conditions, or medications that raise bleeding risk).

In this recommendation statement, the discussion revolves around disease (CVD) risk and the overall benefits of using aspirin with a focus, on categorizing individuals as "men" and "women." However, it is worth noting that CVD risk and estimated benefits are likely influenced by sex (male/female) rather than by gender identity.

Cardiovascular disease is most strongly influenced by age. Men bear more of the brunt for CVD as a whole, whereas females suffer more fatal outcomes from specific cardiovascular events like stroke.

Male CVD sufferers are generally younger than female ones. The CVD prevalence is also varied among different racial and ethnic groups. Of all people, Black Americans have the greatest proportion of CVD patients in both gender categories.

The USPSTF urges usage of ACC/AHA Pooled Cohort Equations to ascertain a person’s risk of developing CVD over 10 years. Out of all American prognostic tools for CVD, it’s only this

The ACC/AHA risk calculator has been externally validated among other American populations. Deliberate calculation includes specific equations for each gender or ethnicity which involve such issues as age, cholesterol concentration, and systolic blood pressure.

It should be noted that one key influence on a 10-year risk estimate for cardiovascular disease using the ACC/AHA tool is increasing age. African Americans tend to have higher values on risk prediction models than White individuals in general.

US Preventative Services Task Force (USPSTF) found that there is limited benefit for aspirin use in preventing cardiovascular disease (CVD) events when ingested by people aged 40-59 who have more than 10% (ten-year) risk. This claim still requires more research. Further, they concluded that it has no benefits for those who are at least 60 years old.

The USPSTF is an organization that offers instructions on how to take aspirin for the first time as a way to prevent heart attacks or strokes. Currently, in the last version updated in 2017 September, USPSTF suggests that:

The American Heart Association (AHA) provides complementary recommendations that align with the USPSTF but offer additional context. According to the AHA:

The guidelines, from the AHA also stress the importance of making lifestyle changes and managing factors that contribute to heart disease like blood pressure, diabetes, and high cholesterol alongside any decision about using aspirin.

Both the USPSTF and AHA recognize the need for an approach when considering aspirin for prevention. While they acknowledge the benefits of aspirin in lowering heart-related issues they also point out the risks of bleeding especially in older individuals.

The alignment of these guidelines on tailoring risk assessment shows a growing agreement within the field. It indicates a shift from recommendations to personalized care. Recent research supports this approach by highlighting that when considering aspirin's advantages one must also carefully evaluate its risks in groups with varying levels of heart disease risk and propensity for bleeding.

When final, the new USPSTF recommendation will update the one from 2016 regarding the use of aspirin to prevent disease (CVD) and colorectal cancer (CRC).

In 2016 it was suggested to start taking dose aspirin for individuals aged 50 to 59 with a 10% or higher 10-year CVD risk without increased bleeding risk and a life expectancy of, over 10 years who are willing to take daily aspirin for at least a decade.

For those aged 60 to 69 with CVD risk, the decision should be individualized. However, there wasn't evidence to evaluate the benefits versus risks for those under 50 or over 70 years old. In the recommendation draft the USPSTF has made changes, in age groups and grades related to aspirin usage.

The USPSTF has, for its present draft recommendation, altered both the ages and grades in its recommendation concerning the use of aspirin. This alteration states that it is advisable for low-dose aspirin to only be started by individuals at 40-59 years who have attained a minimum of 10% 10-year CVD risk. On the other hand, for people aged at least 60 years, it is inappropriate to begin taking low-dose aspirin for primary prevention of CVD.

The USPSTF concluded that available evidence was insufficient for CRC incidence or mortality reduction through the use of low-dose aspirin following new analyses of primary CVD prevention trial data. This is based on long-term follow-up data and new trial evidence.

The antiplatelet effects of aspirin have made it valuable in preventing cardiovascular diseases because significance has been placed on them. Its production is reduced by aspirin in a way that involves blocking the cyclooxygenase-1 enzyme (commonly abbreviated as COX-1). Therefore one may argue that when taken in small doses aspirin reduces heart attack chance.

As we have seen, several recent studies repeatedly show that taking aspirin reduces the risk of CVD occurrences notably from a secondary prevention perspective. People who have previously suffered from heart disease, stroke, or other such ailments should consider using aspirin to prevent further occurrence of these related conditions.

An in-depth report carried out in 2024 highlighted how utilizing aspirin by those already ailing cut down explicitly on negative heart-related events compared to those who stopped using it.

If you want to use aspirin to treat CVD, it is important to know how much is right and how well it works so that you can get as much from it as possible while keeping the risk low. Most recent guidelines recommend a low dose of aspirin (75-100 mg per day) that helps to reduce the risk CVD without significantly increasing the risks of bleeding.

This counsel is particularly critical among individuals with past occurrences, as noted by the American College of Cardiology. When considering the care context, aspirin’s benefits are not straightforward and they must be compared with its disadvantage of causing bleeding risks.

People aged between 40 and 59 whose risk level for CVD is above 10 percent within a span of 10 years might want to think about taking one aspirin daily dose based on new standards released by the United States Preventive Taskforce.

However for individuals aged 60 and above the dangers associated with aspirin therapy, such as bleeding and hemorrhagic stroke often outweigh its benefits.

It is crucial to consider both the benefits and the risks associated with the use of aspirin because it affects cardiovascular health as well as bleeding risks. On the basis of an evaluation of risk factors, the decision of whether to initiate or maintain aspirin therapy can then be taken.

When recommending the treatment of aspirin, health caregivers must put into consideration different factors such as age, past history (CVD), Bleeding risk, and comorbid conditions like diabetes; and hypertension among others.

The trend towards personalized medicine has significantly impacted aspirin therapy. Genetic elements play a role in how an individual responds to aspirin. Variations in genes associated with platelet aggregation pathways could affect how effective and safe aspirin is for people.

ersonalized medicine strategies, such as testing might eventually help customize aspirin therapy to maximize benefits and reduce risks.

The ongoing exploration as an evolving area concerns about the application of aspirin in therapy leading to more optimistic results. There are researches focused on using aspirin in preventing colorectal cancer because it has anti-inflammatory characteristics. To further comprehend dosing schedules as well as combinations of aspirin with other remedies, experiments are also been conducted.

For instance, the results from the ASCEND trial have sparked curiosity about how aspirin can work with medications, like statins to lower cardiovascular risks. The combination therapy mentioned may provide protection, against heart-related issues for high-risk groups like individuals with diabetes

The following requires further study:

The possibility of bleeding when using aspirin is a concern that influences recommendations and patient care strategies. Recent research shows that the chance of experiencing gastrointestinal (GI) bleeding is notably higher in individuals using aspirin compared to those who do not.

For example, a study released in 2020 revealed that among adults the occurrence of GI bleeding was significantly more for those undergoing low-dose aspirin treatment in contrast to those not taking aspirin. This underscores a risk that needs consideration, particularly among groups predisposed to bleeding.

Apart from GI bleeding aspirin also raises the risk of hemorrhage. A comprehensive analysis from 2023 found that using aspirin for prevention was connected to a notable increase in the likelihood of hemorrhagic stroke estimated at roughly an additional 0.3 cases per 1,000 person years.

In addition, to bleeding concerns, there are potential risks and situations where using aspirin may not be advisable:

The following table summarizes the comparative risks of aspirin use in various populations based on recent studies and guidelines:

The American College of Cardiology (ACC) and the American Heart Association (AHA) have recently issued modified set of guidelines which emphasizes the importance of starting aspirin especially when dealing with first-time occurrences.

The guidelines provided do not recommend its use by any individual who is 70 years old and over. It advised that personalized decisions should be made on those aged between 40 and 59 who are at significant danger of contracting cardiovascular diseases.

The use of ultrasound in preventing cardiovascular disease is favored for its non-invasive nature, has become a cornerstone in the early detection and management of cardiovascular diseases. It provides real-time imaging of blood vessels and heart structures, enabling clinicians to identify abnormalities that could predispose individuals to heart attacks and strokes.

One of the most significant applications of ultrasound in preventing cardiovascular disease is the assessment of the carotid arteries. Carotid ultrasound measures the thickness of the carotid artery walls and can detect plaque buildup, which is a predictor of future cardiovascular events. Studies have found that increased carotid intima-media thickness (CIMT) is associated with a higher risk of myocardial infarction and stroke​​.

Ultrasound can determine if the lump is solid tissue or a fluid-filled cyst, helping to characterize an abnormality that has been detected.

Echocardiography is another important application of ultrasound, It gives detailed images of a person’s structure and function. This allows physicians to diagnosis conditions like left ventricular hypertrophy early.

Stress echocardiography combines ultrasound imaging with exercise to see how a person’s heart functions under stress conditions. This test can help to pin-point ischemic heart disease by showing exactly which areas of the heart receive inadequate blood flow during stress. Identifying such areas early is important for timely intervention.

Encouraging shared decision-making (SDM) a collaborative process that promotes patient-clinician discussions is crucial. SDM empowers patients to actively participate in their healthcare choices by combining evidence with preferences, values, and goals to ensure that medical decisions align with the patient's priorities.

Patient-clinician conversations are essential for many reasons. They improve satisfaction and trust as studies indicate that patients engaged in SDM express contentment with their care and are more likely to follow treatment plans. This is because they feel their opinions and values are valued, fostering a sense of responsibility, for their health choices.

Patients who engage in shared decision-making (SDM) are less likely to resort to action after experiencing outcomes. They view the decision-making process as transparent and inclusive fostering trust and understanding, between healthcare providers and patients.

Furthermore, SDM empowers patients to comprehend the risks and benefits of treatment options. Through discussions about outcomes and alternatives, healthcare professionals can assist patients in making well-informed choices that suit their individual circumstances and health objectives.

This becomes especially critical in situations where multiple viable options present differing sets of advantages and disadvantages.

In order to support shared decision making a range of tools and resources have been created. One such tool is the BRAN questions framework, which encourages patients to ask:

By guiding patients through these considerations this framework promotes discussions that lead to decisions.

Decision aids serve as another resource for facilitating shared decision-making. These aids come in formats such as brochures, videos, or interactive online tools. They offer evidence-based information on treatment options along, with their associated risks and benefits.

Decision support tools are created to enhance the expertise of healthcare providers helping patients grasp their options better and enabling dialogues during medical appointments​.

Despite its advantages, SDM encounters hurdles. Time limitations during consultations pose a challenge. Many clinicians feel compelled to make decisions due to restricted appointment durations, which can impede in-depth conversations, with patients.

To tackle this issue healthcare systems could dedicate time to consultations involving decisions and provide assistance from support staff, for patient education (AMA Ethics). Another obstacle is the variation in patients' preferences regarding involvement in decision-making.

Some patients like to leave decisions to their healthcare providers while others like to involve themselves.Like different people have different tastes,patients do not resemble when it comes to assuming who should make decisions for them concerning the type of treatment that one is supposed to undergo.

This might entail employing communication techniques and decision-making tools tailored to match the level of engagement desired by the patient (SGIM)​.

The U.S. Preventive Services Task Force (USPSTF) and the American College of Cardiology/American Heart Association (ACC/AHA) recently released new guidelines on aspirin use for primary prevention of cardiovascular disease (CVD), focusing more on tailoring individualized treatment schedules to each patient’s specific risks and advantages.

By 2022, the USPSTF is opposed to recommending the start of low-dose aspirin to prevent CVD among adults who are 60 years old or more years. The proposal has been made based on studies that show that more people in this age category experience and often die from heart attacks or strokes.

According to the USPSTF, starting low-dose of aspirin for adults ages 40 to 59 years whose ten-year risk of coronary vascular disease (CVD) is 10% or higher should depend on personal judgment. Therefore, conversations between patients and health practitioners are vital when figuring out if one should start taking aspirin because it is important to remember that benefits may come with risks like excess bleeding.

The ACC/AHA 2019 guidelines additionally supports personalized healthcare for at-risk patients between 40 and 70 years of age. They advice not to use aspirin for prevention among those aged over 70 years or with a bleeding risk on the basis of conditions such as previous gastrointestinal bleedings or certain medicines that increase bleeding risks.

They emphasise that balance in using aspirin for CVD prevention requires continuous monitoring and follow up with your healthcare provider's instructions as well, preventing events and minimizing bleeding risks​.

Patients who use aspirin to prevent cardiovascular diseases need to be monitored and followed up frequently. Medical checks will help in balancing benefits of cardiovascular events prevention and risk of increased bleeding.

Individuals prescribed aspirin for a period should undergo assessments to gauge their risk of cardiovascular events and potential bleeding issues. This involves monitoring changes, in their health identifying any risk factors that may have arisen, and keeping an eye out for any negative effects experienced while taking aspirin.

Tools such as the ACC/AHA pooled cohort equations (PCE) can be utilized to predict the 10-year disease (CVD) risk and provide guidance for decisions according to information from the American Heart Association (AHA) and Cleveland Clinic Journal of Medicine (CCJM).

Since aspirin has an increased potential for serious bleeding episodes, it is important to watch out for either intestinal or intracranial bleeding symptoms among other complications. Symptoms include cuts that bleed and take longer to heal, blood in stools or urine and severe headaches.

Various tools and resources are accessible to aid healthcare providers in making informed decisions together with patients. For example, the Predicting Risk of Death in Cardiac Disease Tool (PREDICT) is a model developed in New Zealand that helps estimate the absolute bleeding risk linked with aspirin when used for primary prevention purposes.

Educating patients is very critical when it comes to the possible advantages or hazards of aspirin medication. Involving lifestyle changes that can cut down on coronary vascular disease threat, like healthy eating habits, regular physical exercises, stopping smoking and managing diabetes and hypertension disorders among others.

These tools used for decision making alongside educational materials will help guide the conversation so that patients can choose based on knowledge as far as health is concerned. In summary, the choice to initiate or continue aspirin therapy for preventing CVD should be tailored to each individual's needs, for individuals.

Continuous monitoring and patient education are aspects of overseeing aspirin treatment to strike a balance between preventing events and the risk of severe bleeding. Both USPSTF and ACC/AHA guidelines stress the importance of customized treatment plans and regular evaluations to enhance outcomes.

For both patients and healthcare providers having access, to resources and tools can significantly impact the prevention and control of disease (CVD).

Here are some new and valuable resources available:

prioritizing care for heart health is crucial in medicine highlighting the importance of personalized treatment. While using aspirin can be beneficial for individuals in preventing heart issues it's essential to weigh its risks carefully.

Decisions regarding aspirin usage should involve shared discussions between patients and healthcare providers based on factors and preferences. Keeping up with updated guidelines from organizations like USPSTF and AHA can guide clinicians but customizing these recommendations for each patient is key.

The use of ultrasound in preventing cardiovascular disease can aid in preventing cardiovascular disease. Its ability to detect early signs of atherosclerosis and other cardiovascular abnormalities enables healthcare professionals to implement timely and effective preventive strategies

Combining ultrasound with traditional preventive measures like aspirin therapy can significantly reduce the burden of cardiovascular disease and improve patient outcomes.

1. A study of cardiovascular events in Diabetes - American College of Cardiology. (2018, August 25). American College of Cardiology.

2. ASCEND: A Study of Cardiovascular Events IN Diabetes. (n.d.). Haiku.

3. ASCVD Risk Estimator +. (n.d.).

4. Cardiovascular Diseases | NCD Alliance. (2022, September 29). NCD Alliance.

5. Daily aspirin therapy: Understand the benefits and risks. (2023, April 20). Mayo Clinic.

6.  E Mahady, S. (2023, August 3). Major GI bleeding in older persons using aspirin: Incidence and risk factors in the ASPREE randomised controlled trial. National Library of Medicine.

7. Guidelines & Clinical Documents - American College of Cardiology. (n.d.). American College of Cardiology.

8. Harvard Health. (2024, April 5). Proton-pump inhibitors: What you need to know.

9. Home | CardioSmart – American College of Cardiology. (n.d.). CardioSmart.

10. Life’s Essential 8. (n.d.). www.heart.org.

11. McNeil, J. J., Nelson, M. R., Woods, R. L., Lockery, J. E., Wolfe, R., Reid, C. M., Kirpach, B., Shah, R. C., Ives, D. G., Storey, E., Ryan, J., Tonkin, A. M., Newman, A. B., Williamson, J. D., Margolis, K. L., Ernst, M. E., Abhayaratna, W. P., Stocks, N., Fitzgerald, S. M., . . . Murray, A. M. (2018). Effect of Aspirin on All-Cause mortality in the healthy elderly. New England Journal of Medicine/˜the œNew England Journal of Medicine, 379(16), 1519–1528.

12. Medina-Inojosa, J. R., Somers, V. K., Garcia, M., Thomas, R. J., Allison, T., Chaudry, R., Wood-Wentz, C. M., Bailey, K. R., Mulvagh, S. L., & Lopez-Jimenez, F. (2023). Performance of the ACC/AHA pooled cohort cardiovascular risk equations in clinical practice. Journal of the American College of Cardiology, 82(15), 1499–1508.

13. New USPSTF recommendation on aspirin in CVD: No for primary prevention, Yes for secondary prevention - American College of Cardiology. (2022, April 27). American College of Cardiology.

14. NICE. (2023, December 14). Overview | Cardiovascular disease: risk assessment and reduction, including lipid modification | Guidance | NICE.

15. PAHO. (2024). WHO/PAHO Technical Advisory Group on Cardiovascular Disease Prevention through Dietary Salt/Sodium Reduction: Final Report Phase 3. iris.paho.org.

16. Shared decision making. (n.d.). Centre for Perioperative Care.

17. Slofstra, S. H., Cate, H. T., & Spek, C. A. (2006). Signal transduction induced by activated protein C: no role in protection against sepsis? Trends in Molecular Medicine, 12(8), 374–381.

18. Three decades of UpToDate. (n.d.). [Video].

19. Website, N. (2024, May 7). Cardiovascular disease. nhs.uk.